The Double Role of Lipids: Fueling Cancer and Hiding it From the Immune System

 

One of the most complicated diseases is cancer, and researchers have been working to learn more about how it develops, spreads, and eludes the body's defenses. The function of lipids—fatty molecules that were previously believed to be merely sources of energy for tumors—is one of the startling discoveries in the study of cancer. However, indicates that certain lipids are essential for cancer cells to evade the immune system. This finding provides a fresh approach to creating cancer treatments that work better.

The capacity of cancer cells to evade immune system detection is well-known. Normally, the immune system is built to identify and eliminate rogue or aberrant cells, including malignant ones. Nevertheless, a lot of tumors change their surface signals to make themselves "invisible" to immune cells, avoiding this immunological reaction.

Sphingolipids in particular are becoming important components of this immunological evasion tactic. Previously thought to be utilized solely for energy, it turns out that some lipids also serve to conceal the cancer cells from immune monitoring. This misunderstanding permits cancer to spread unchecked, resulting in tumors that are more aggressive.

In order to overcome this difficulty, researchers are currently investigating ways to interfere with the lipid synthesis process in cancer cells. They have discovered that sphingolipids play a crucial role in cancer cells' ability to avoid immune system recognition. By preventing the production of these lipids, they can expose cancer cells to the immune system and increase their susceptibility to assault. One method that shows promise is the use of FDA-approved medications that prevent the synthesis of glycosphingolipids. These medications were initially created to treat lipid storage diseases, but they have also demonstrated the ability to stop the growth of tumors in cancers like colorectal, lung, and pancreatic issues. These medications can eliminate the cancer cells' defenses by stopping the development of lipid "nanodomains" that the cells utilize to conceal inflammatory signals.

The capacity of this treatment to strengthen the immune system's reaction accounts for its efficacy. These medications change the surface of cancer cells to increase their immune system detectability by focusing on the formation of glycosphingolipids. The immune system may identify cancer cells as dangers and react appropriately after they are unable to defend themselves with lipids. This strategy is especially pertinent to KRAS-mutated tumors, which are infamously challenging to cure. Pancreatic cancer and other KRAS-dependent malignancies are frequently very aggressive and resistant to many treatments. Disrupting the manufacture of glycosphingolipids, however, might provide a novel approach to increase these malignancies' vulnerability to currently available immunotherapies.

The mechanisms underlying this immune evasion based on lipids are intriguing. In order to arrange signaling molecules in a way that skews the cell's inflammatory signals, cancer cells employ sphingolipids to form scaffolding on their membranes. These lipid structures, referred to as "nanodomains," assemble receptors that ordinarily notify the immune system when a cancer cell is present. The cancer cells successfully "turn off" the immune response by tampering with these signals. When sphingolipid synthesis is disrupted, these nanodomains cease to develop, exposing the cancer cells. They become far more susceptible to immune cell attack as a result. Put another way, lipids serve as a barrier for cancer cells, and removing this barrier may be the secret to its destruction.

The identification of lipids' function in cancer immune evasion creates new therapeutic opportunities. A possible tactic to support current cancer treatments is to target lipid metabolism, particularly by glycosphingolipid inhibition. This method not only cuts off the cancer cells' energy source but also eliminates their barrier, which improves the immune system's ability to function.

REFERENCES

Soula, M., Unlu, G., Welch, R. et al. Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer. Nature 633, 451–458 (2024). https://doi.org/10.1038/s41586-024-07787-1

IMAGE SOURCE

https://www.jax.org/explore-by-topic/cancer-tumors